| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C19H15F4NO3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active activator of the PI3K/Akt/CREB pathway. It promotes neuronal proliferation, drives differentiation of Neuro-2a cells into a neuron-like morphology, and accelerates axon-dendrite polarization of primary hippocampal neurons by upregulating brain-derived neurotrophic factor through this pathway, and it can be used in vascular dementia (VaD) research[1]. It is supplied as a white to off-white solid (C19H15F4NO3, MW 381.32) at 98.64% purity.
Physical & Chemical Properties
| CAS Number | 2708177-73-3 |
|---|---|
| Molecular Formula | C19H15F4NO3 |
| Molecular Weight | 381.32 g/mol |
| Purity | 98.64% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(N[C@H](C(O)=O)CC1=CC=C(C=C1)F)/C=C/C2=CC=C(C=C2)C(F)(F)F |
| Signaling Pathway | PI3K/Akt/mTOR; Epigenetics |
| Solubility | In Vitro: DMSO: 250 mg/mL (655.62 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 250 mg/mL (655.62 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.45 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.45 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
In Neuro-2a cells, PI3K/Akt/CREB activator 1 (compound AE-18) at 10 and 20 μM for 48 h induces neurite outgrowth and proliferation by upregulating BDNF through the PI3K/Akt/CREB pathway[1]. In cultured hippocampal neurons, 10 and 20 μM PI3K/Akt/CREB activator 1 enhances neuronal differentiation and axon-dendrite polarization through the PI3K/AKT signal pathway[1].
Western Blot Analysis[1]
| Cell Line | Neuro-2a cells |
|---|---|
| Concentration | 10 and 20 μM |
| Incubation Time | 48 hours |
| Result | Increased the expressions of BDNF and the phosphorylated form of AKT (pAKT) and CREB (pCREB). |
In Vivo
In male Sprague-Dawley rats with a chronic cerebral hypoperfusion (CCH) model, PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.) improves recovery of cerebral blood flow (CBF) following bilateral common carotid artery occlusion (BCCAO)[1]. Given i.g. at 5 and 10 mg/kg for 5 d, PI3K/Akt/CREB activator 1 lessens the impairment of learning and memory in the CCH rat model and relieves CCH-induced hippocampal pathological injury after BCCAO[1].
| Animal Model | Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model[1] |
|---|---|
| Dosage | 5 and 10 mg/kg |
| Administration | Oral gavage; daily, for 6 weeks |
| Result | Promoted the recovery of CBF after BCCAO. |
| Animal Model | Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model[1] |
|---|---|
| Dosage | 5 and 10 mg/kg |
| Administration | Oral gavage; daily, for 5 days |
| Result | Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group. Improved cognitive deficits in CCH rat model. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Post-stroke hippocampal neurogenesis is impaired by microvascular dysfunction and PI3K signaling in cerebral amyloid angiopathy. Cell Rep 2024 Oct 10;43(10):114848. PMID: 39392753
Bufotalin targets COL1A1 to suppress non-small cell lung cancer growth and remodel the tumor microenvironment via dual inhibition of PI3K/AKT/mTOR and MAPK pathways. Eur J Pharmacol 2026 Feb 15:1015:178601. PMID: 41581717
SHP2 induced ferroptosis resistance in hepatocellular carcinoma via modulating CREB/EZH2/FOXO1 signaling induced autophagy/NCOA4/GPX4 protein expression. Sci Rep 2026 Jul 1. PMID: 42387040
Celastrol inhibits mouse B16-F10 melanoma cell survival by regulating the PI3K/AKT/mTOR signaling pathway and repressing HIF-1α expression. Discov Oncol 2024 May 21;15(1):178. PMID: 38771435
University of Miami. 2025.
